Clinical efficacy and tumour microenvironment influence of decitabine plus R‐CHOP in patients with newly diagnosed diffuse large B‐Cell lymphoma: Phase 1/2 and biomarker study | Zendy

Zhang MuChen | Zendy; Fang Ying | Zendy; Xu PengPeng | Zendy; Dong Lei | Zendy; Shen Rong | Zendy; Huang YaoHui | Zendy; Fu Di | Zendy; Yan ZiXun | Zendy; Cheng Shu | Zendy; Jiang XuFeng | Zendy; Song Qi | Zendy; He Yang | Zendy; Zhao Yan | Zendy; Lu Min | Zendy; Ye Jing | Zendy; Liu Feng | Zendy; Cheng Lin | Zendy; Wang ChaoFu | Zendy; Wang Li | Zendy; Zhao WeiLi | Zendy

Open Access

Clinical efficacy and tumour microenvironment influence of decitabine plus R‐CHOP in patients with newly diagnosed diffuse large B‐Cell lymphoma: Phase 1/2 and biomarker study

Author(s) -

Zhang MuChen,

Fang Ying,

Xu PengPeng,

Dong Lei,

Shen Rong,

Huang YaoHui,

Fu Di,

Yan ZiXun,

Cheng Shu,

Jiang XuFeng,

Song Qi,

He Yang,

Zhao Yan,

Lu Min,

Ye Jing,

Liu Feng,

Cheng Lin,

Wang ChaoFu,

Wang Li,

Zhao WeiLi

Publication year - 2021

Publication title -

clinical and translational medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.125

H-Index - 1

ISSN - 2001-1326

DOI - 10.1002/ctm2.584

Subject(s) - decitabine , medicine , diffuse large b cell lymphoma , international prognostic index , tolerability , oncology , vincristine , rituximab , lymphoma , gastroenterology , adverse effect , cyclophosphamide , chemotherapy , dna methylation , biology , biochemistry , gene , gene expression

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog